CAC2 Childhood Cancer Community News Digest (October 9-15)

Assorted News from the Last Week:

Video distraction minimizes anesthesia for children undergoing radiotherapy.

Supporting the family affected by a pediatric cancer diagnosis: siblings matter, too.

From the Journal of Clinical Oncology: Chromosomal gains as a favorable prognostic factor in pediatric ALL.

A teen’s guide to everything cancer.

Cancer in kids is different from cancer in grown-ups – figuring out how could lead to better pediatric treatment.

Perception of infertility risk mostly inaccurate among young female cancer survivors.

Increased surgical duration was found to be an independent risk factor for surgical site infection in patients with lower extremity bone tumors undergoing endoprosthetic reconstruction after tumor resection.

Upcoming Webinars, Online Opportunities, and Meetings:

Join leaders and advocates across pediatric cancer as we come together on October 18-19 for CureSearch’s virtual 2023 Pediatric Early Development Symposium.  Learn more and register.

On October 24 at 2:00 ET, Dr. Angela Mariotto, chief of the Data Analytics Branch in NCI’s Division of Cancer Control and Population Sciences, will showcase the combined potential of NCCR*Explorer and SEER*Stat, two tools available through the CCDI National Childhood Cancer Registry (NCCR). Through a live demonstration and real-world examples, attendees will learn how to harness these resources for cancer research and surveillance. Attendees will also have the chance to ask questions during the session’s Q&A. Register.

Join top scientific experts, clinicians, researchers, NCI, childhood cancer foundations and advocates, agency officials, and many more for the Inaugural Childhood Cancer Prevention Symposium.  This ground breaking meeting will take place at Children’s National Research & Innovation Campus in Washington, DC on October 25-26th, 2023.  (Registration and meeting details forthcoming shortly).

Join the Ross K. MacNeill Foundation at their 2023 Orange Tie Gala for pediatric brain cancer research, November 4, 6:30-11:00pm CT.  Learn more and register.

Recent Recordings:

Alejandro Sweet-Cordero, MD, University of California-San Francisco presents on “Genomic analysis of osteosarcoma: Making sense of a complex genome to advance translational research and targeted therapy.”

How my cancer journey led me to help patients facing food insecurity.”

Take Action:

A Draft Scientific Integrity Policy of the National Institutes of Health was released for public comment. The draft policy articulates the procedures and processes in place at NIH that help maintain rigorous scientific integrity practices. Additionally, the draft policy proposes several new functions to further enhance scientific integrity at NIH and throughout the biomedical research enterprise.  Comments will be accepted until November 9, 2023.

Phase 1/2 trial which aims to determine the safety and feasibility of anti-CD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.

International Children’s Palliative Care Network (ICPCN) are excited to announce that the 2023 Digital Toolkithas been officially launched and is now available to download on the ICPCN #HatsOn4CPC website page. The #HatsOn4CPC annual campaign will be held on Friday 13th October 2023.

To help spread the word about the Childhood Cancer Data Initiative (CCDI), the National Cancer Institute has created a communications toolkit with a CCDI overview flyer, a one-pager with frequently asked questions about the CCDI Data Ecosystem, and sample social media posts and graphics.  Access the toolkit, and feel free to reference, copy, and use its content for inspiration.


Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

This field is for validation purposes and should be left unchanged.